Navigation Links
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Date:2/1/2012

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines.  A number of products developed with this technology are currently in clinical development.  The patent helps to secure the novel Antigen Express vaccine technology platform in the international community.  International counterparts have been granted in Australia, China, and the United States.  The European counterpart has been allowed, and the Canadian application is pending.

(Photo:  http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs.  The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.  Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37).  This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says ... been known to react more aggressively when hormones change, and ... puberty, other acne causing factors like P.acnes bacteria and excess ... with unsightly acne scars. Adult acne treatment, Probiotic Action shares ... how to reduce and prevent acne scarring. , In order ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... ... and Ralph M. Lerner named Senior Vice President of Commercial Development , ... Marlborough, Mass. (Vocus) October 23, ... technology turns biomass into cellulosic ethanol, has welcomed Kevin F. McLaughlin and Ralph M. ...
... Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ... overview of the Company at the 8th Annual BIO ... 3:00 p.m. PT. The conference will be held at ... and 29, 2009. , A live audio link to ...
... Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and ... previously announced registered direct offering of US$5.5 million ... share purchase warrants to certain institutional investors. AEterna ...
Cached Biology Technology:Cellulosic Biofuels Leader Qteros Adds Key Positions 2Cellulosic Biofuels Leader Qteros Adds Key Positions 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 3
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... 2013) Illustrating a commitment to the support ... Association (AGA) Research Foundation has announced the inaugural ... Award recipients. Supported by the National Institute of ... new award helps underrepresented minority students to further ... research. , "By establishing this new award, AGA ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... in partnership with Oak Ridge National Laboratory (ORNL) will ... the National Science Foundation (NSF) has deemed the "most ... The two will team up to participate ... continental-scale ecological observatory, to answer questions that deal with ...
... Mass. A six-year campaign to control invasive winter ... Elkinton of the University of Massachusetts Amherst now has ... been established and is attacking the pest at four ... beginning of the end for the decade-long defoliation of ...
... (Santa Barbara, Calif.) Sensors made from custom DNA molecules ... quality of stem cells, according to an international team of ... University of Rome Tor Vergata. The new nanosensors can ... which serve as the master control switches of life. The ...
Cached Biology News:University of Tennessee chosen to join national network to study climate change 2UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts 2Nanosensors made from DNA may light path to new cancer tests and drugs 2Nanosensors made from DNA may light path to new cancer tests and drugs 3
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Biology Products: